LifeStance Data Shows 79% Anxiety, 73% Depression Improvement in 180,000 Patients
LifeStance’s analysis of 180,000 patients treated from September 2024 to December 2025 shows 79% anxiety improvement and 73% depression improvement across 33 states. Regular GAD-7 and PHQ-9 assessments enabled clinicians to adjust care and achieve consistent results nationwide.
1. Clinical Outcomes Analysis
LifeStance evaluated 180,000 patients who began treatment between September 2024 and December 2025, finding 79% of individuals with moderate or worse anxiety and 73% with moderate or worse depression experienced clinically significant symptom improvements.
2. Measurement-Informed Care Model
Patients complete GAD-7 and PHQ-9 assessments at regular intervals, allowing clinicians to monitor progress quantitatively and adjust therapy or medication management in real time to optimize treatment outcomes.
3. National Scale and Reach
The study encompasses 33 states across more than 550 centers, with outcomes consistent across all U.S. regions; LifeStance’s hybrid in-person and telehealth network supports broad access and patient engagement.
4. Strategic Implications
Demonstrating high treatment efficacy at scale reinforces LifeStance’s value proposition for payers and referral partners, potentially driving increased demand, patient volume growth, and bolstering investor confidence in clinical performance.